Literature DB >> 20079331

Categorical and dimensional stability of comorbid personality disorder symptoms in DSM-IV major depressive disorder: a prospective study.

Tarja K Melartin1, Jari Haukka, Heikki J Rytsälä, Pekka J Jylhä, Erkki T Isometsä.   

Abstract

OBJECTIVE: To investigate the categorical and dimensional temporal stability of Axis II personality disorders among depressive patients, and to determine whether variations in Axis I comorbid disorders or self-reported personality traits predict changes in researcher-assigned personality disorder symptoms.
METHOD: Patients with DSM-IV major depressive disorder (MDD) in the Vantaa Depression Study (N = 269) were interviewed with the World Health Organization Schedules for Clinical Assessment in Neuropsychiatry, version 2.0, and the Structured Clinical Interview for DSM-III-R Axis II Disorders and were assessed with the 57-item Eysenck Personality Inventory at baseline, 6 months, and 18 months. Baseline interviews occurred between February 1, 1997, and May 31, 1998; follow-up interviews were 6 months and 18 months after baseline for each patient. Of the patients included in the study, 193 remained unipolar and could be interviewed at both follow-ups. The covariation of the severity of depression, anxiety, alcohol use, and reported neuroticism and extraversion with assigned personality disorder symptoms was investigated by using general estimation equations.
RESULTS: The diagnosis of personality disorder persisted at all time points in about half (43%) of the 81 MDD patients diagnosed with personality disorder at baseline. The number of positive personality disorder criteria declined, particularly during the first 6 months, by a mean of 3 criteria. The decline in reported personality disorder symptoms covaried significantly with declines in the severity of depressive and anxiety symptoms (depressive: P = .02 for paranoid, P = .02 for borderline, and P = .01 for avoidant; anxiety: P = .08 for paranoid, P = .01 for borderline, and P < .001 for avoidant). Changes in patients' perceptions of self as measured by neuroticism covaried with changes in paranoid (P = .01) and borderline (P < .001) personality disorder symptoms.
CONCLUSIONS: Among MDD patients, the categorical stability of concurrent personality disorder diagnoses assigned while depressed is relatively poor, but the dimensional stability is moderate. The remission of depression as well as variations in Axis I comorbidity, particularly anxiety disorders, influences personality disorder diagnoses. These diagnostic difficulties most likely reflect broader variations in patients' perceptions of self over time, not merely psychometric problems related to the pertinent diagnostic criteria. (c) 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20079331     DOI: 10.4088/JCP.08m04621blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  Prevalence of personality disorders using two diagnostic systems in psychiatric outpatients in Shanghai, China: a comparison of uni-axial and multi-axial formulation.

Authors:  Tianhong Zhang; Lanlan Wang; Mary-Jo D Good; Byron J Good; Annabelle Chow; Yunfei Dai; Junhan Yu; Haiyin Zhang; Zeping Xiao
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2011-12-08       Impact factor: 4.328

2.  Personality disorder assessments in acute depressive episodes: stability at follow-up.

Authors:  Jorge Lopez-Castroman; Hanga Galfalvy; Dianne Currier; Barbara Stanley; Hilario Blasco-Fontecilla; Enrique Baca-Garcia; Jill Martine Harkavy-Friedman; Joseph John Mann; Maria Antonia Oquendo
Journal:  J Nerv Ment Dis       Date:  2012-06       Impact factor: 2.254

3.  Do Suicide Attempts of Mood Disorder Patients Directly Increase the Risk for a Reattempt?

Authors:  Kari I Aaltonen; Tom Rosenström; Pekka Jylhä; Irina Holma; Mikael Holma; Sanna Pallaskorpi; Kirsi Riihimäki; Kirsi Suominen; Maria Vuorilehto; Erkki T Isometsä
Journal:  Front Psychiatry       Date:  2020-11-26       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.